Scientific Reports (Sep 2023)

Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023

  • Jira Chansaenroj,
  • Nungruthai Suntronwong,
  • Sitthichai Kanokudom,
  • Suvichada Assawakosri,
  • Preeyaporn Vichaiwattana,
  • Sirapa Klinfueng,
  • Lakana Wongsrisang,
  • Thanunrat Thongmee,
  • Ratchadawan Aeemjinda,
  • Nongkanok Khanarat,
  • Donchida Srimuan,
  • Thaksaporn Thatsanathorn,
  • Ritthideach Yorsaeng,
  • Apirat Katanyutanon,
  • Wichai Thanasopon,
  • Wichan Bhunyakitikorn,
  • Chaninan Sonthichai,
  • Piyada Angsuwatcharakorn,
  • Withak Withaksabut,
  • Nasamon Wanlapakorn,
  • Natthinee Sudhinaraset,
  • Yong Poovorawan

DOI
https://doi.org/10.1038/s41598-023-42754-2
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Seroprevalence studies on SARS-CoV-2 are essential for estimating actual prevalence rates of infection and vaccination in communities. This study evaluated infection rates based on total anti-nucleocapsid immunoglobulin (N) and/or infection history. We determined the seroprevalence of anti-receptor binding domain (RBD) antibodies across age groups. A cross-sectional study was conducted in Chonburi province, Thailand, between October 2022 and January 2023. Participants included newborns to adults aged up to 80 years. All serum samples were tested for anti-N total Ig and anti-RBD IgG. The interviewer-administered questionnaires queried information on infection history and vaccination records. Of 1459 participants enrolled from the Chonburi population, ~ 72.4% were infected. The number of infections was higher in children aged 60 years. Our findings will help predict the exact number of infections and the seroprevalence of SARS-CoV-2 in the Thai population. Furthermore, this information is essential for public health decision-making and the development of vaccination strategies.